179 related articles for article (PubMed ID: 35977314)
1. Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps.
Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Basch E; Keating NL
JAMA Health Forum; 2021 May; 2(5):e210673. PubMed ID: 35977314
[TBL] [Abstract][Full Text] [Related]
2. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
3. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
[No Abstract] [Full Text] [Related]
4. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.
Jazowski SA; Wilson L; Dusetzina SB; Zafar SY; Zullig LL
JAMA Netw Open; 2022 Jun; 5(6):e2215720. PubMed ID: 35671056
[TBL] [Abstract][Full Text] [Related]
5. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps.
Yeung K; Barthold D; Dusetzina SB; Basu A
N Engl J Med; 2020 Aug; 383(6):558-566. PubMed ID: 32757524
[TBL] [Abstract][Full Text] [Related]
6. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
Vyas A; Descoteaux A; Kogut S; Parikh MA; Campbell PJ; Green A; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):831-844. PubMed ID: 35876294
[No Abstract] [Full Text] [Related]
7. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
9. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.
Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Wood WA; Olszewski A; Basch E; Keating NL
J Natl Cancer Inst; 2020 Oct; 112(10):1055-1062. PubMed ID: 31883008
[TBL] [Abstract][Full Text] [Related]
10. Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
Garabedian LF; Zhang F; Costa R; Argetsinger S; Ross-Degnan D; Wharam JF
Ann Intern Med; 2024 Apr; 177(4):439-448. PubMed ID: 38527286
[TBL] [Abstract][Full Text] [Related]
11. Impact of out-of-pocket spending caps on financial burden of those with group health insurance.
Riggs KR; Buttorff C; Alexander GC
J Gen Intern Med; 2015 May; 30(5):683-8. PubMed ID: 25472507
[TBL] [Abstract][Full Text] [Related]
12. Prescription Drug Dispensing and Patient Costs After Implementation of a No Behavioral Health Cost-Sharing Law.
Golberstein E; Campbell JM; Maclean JC; Harris SJ; Saloner B; Stein BD
JAMA Health Forum; 2024 Mar; 5(3):e240198. PubMed ID: 38517423
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Spending for Patients Initiating Dialysis Care.
League RJ; Eliason P; McDevitt RC; Roberts JW; Wong H
JAMA Netw Open; 2022 Oct; 5(10):e2239131. PubMed ID: 36306129
[TBL] [Abstract][Full Text] [Related]
14. Out-of-Pocket Spending for Hospitalizations Among Nonelderly Adults.
Adrion ER; Ryan AM; Seltzer AC; Chen LM; Ayanian JZ; Nallamothu BK
JAMA Intern Med; 2016 Sep; 176(9):1325-32. PubMed ID: 27367932
[TBL] [Abstract][Full Text] [Related]
15. Gaining Coverage Through Medicaid Or Private Insurance Increased Prescription Use And Lowered Out-Of-Pocket Spending.
Mulcahy AW; Eibner C; Finegold K
Health Aff (Millwood); 2016 Sep; 35(9):1725-33. PubMed ID: 27534776
[TBL] [Abstract][Full Text] [Related]
16. Association of Federal Mental Health Parity Legislation With Health Care Use and Spending Among High Utilizers of Services.
Haffajee RL; Mello MM; Zhang F; Busch AB; Zaslavsky AM; Wharam JF
Med Care; 2019 Apr; 57(4):245-255. PubMed ID: 30807450
[TBL] [Abstract][Full Text] [Related]
17. Out-of-Pocket Spending for Non-Birth-Related Hospitalizations of Privately Insured US Children, 2017 to 2019.
Carlton EF; Becker NV; Moniz MH; Scott JW; Prescott HC; Chua KP
JAMA Pediatr; 2023 May; 177(5):516-525. PubMed ID: 36972040
[TBL] [Abstract][Full Text] [Related]
18. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Sharing Drug Rebates at the Point of Sale on Out-of-Pocket Payments for Enrollees in Employer-Sponsored Insurance.
Ding Y; Miller GE
Value Health; 2023 Feb; 26(2):226-233. PubMed ID: 36114087
[TBL] [Abstract][Full Text] [Related]
20. The effects of mental health parity on spending and utilization for bipolar, major depression, and adjustment disorders.
Busch AB; Yoon F; Barry CL; Azzone V; Normand SL; Goldman HH; Huskamp HA
Am J Psychiatry; 2013 Feb; 170(2):180-7. PubMed ID: 23377639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
